Home > Oncology > WCLC 2019 > Targeted Therapy > Older Age and Low Neutrophilia Inflammation Predictor for Osimertinib Efficacy

Older Age and Low Neutrophilia Inflammation Predictor for Osimertinib Efficacy

Conference
WCLC 2019

Osimertinib – a third generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) – has shown highly significant efficacy in non-small-cell lung cancer (NSCLC) patients with sensitive mutations as well as in patients with a T790M resistance mutation. EGFR T790M is a robust biomarker for the efficacy of osimertinib. Still, in a number of patients with NSCLC who harbour the EGFR T790M mutation, clinical efficacy remains very limited, which suggests primary resistance.

Jang et al. aimed to discover clinical predictive factors for the efficacy of osimertinib, and analysed patients with stage IV, EGFR T790M+ lung adenocarcinoma who were given osimertinib as salvage treatment in a retrospective study [1]. Various baseline clinical factors were investigated according to favourable or unfavourable osimertinib efficacy group. Unfavourable efficacy (primary resistance) was defined as progression-free survival (PFS) <6 months wi...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on